rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2004-806rsp-943Research ArticleСтатьиArticlesМесто сульфасалазина в комплексной терапии серонегатннных спондилоартритовPlace of sulfasalazine in complex treatment of seronegative spondylarthritiesБадокинВ. В.BadokinV V-200415082004424№4 (2004)6872Copyright © Бадокин В.В., 20042004Бадокин В.В.Badokin V.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/943References<div><p>Бадокин В.В., Агабабова Э.Р., Шубин С.В. Место глюкокортикостероидов в терапии серонегативных спон- дилоартритов. Научно-практическая ревматология, 2001, 4, 48-55</p><p>Насонова В.А., Насонов ЕЛ. Рациональная фармакотерапия ревматических заболеваний. М., Литтерра, 2003</p><p>Чепелева С.Н., Сигиднн Я.А., Лукина Г.В. Контролируемая оценка эффективности сульфасалазина при ан- килозирующем спондилоартрите. Научно-пракгич. ревматол., 2001, 4, 32-36</p><p>Altan L., Bingo! U., Karakos Y. et al. Clinical investigation of methotrexate in the treatment of ankylosing spondylitis. Scand. J. Rheumatol. 2001, 30, 255-259</p><p>Amor B. Data management in spondylarthropathies. Rheumatol, in Europe, 1996, 25, 92-95</p><p>Amor B., Dougados М., Kahn M.A. Management of refractory ankylosing spondylitis and related spondyloarthropathies. Rheum. Dis. North Am., 1995, 21, 117-126</p><p>Brandt J., Buss B., Sieper J., Braun.1. Efficacy of treatment with sulphasalazine versus azathioprine in ankylosing spondylitis. J. Rheumatol. 2000, 27, suppl. 59, 182-184</p><p>Braun J, Sieper J. Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases. Expert Opin. Biol. Ther., 2003, 3, 141-168</p><p>Calin A., Tnurog J.D. Spondylarthritides. Oxford University Press, 1998</p><p>Clegg D.O., Reda D.J., Mejias E. et al. Comparison of sulphasalazine and placebo for the treatment of psoriatic arthritis and cutaneous psoriasis. Arthr. Rheum., 1996, 39, 2013-2020</p><p>Clegg D.O., Rede D.J., Weisman M.N. et al. Comparison of sulphasalazine and placebo in the treatment of reactive arthritis (Reiterys syndrome). A Department of Veterans Affairs Cooperative study. Arthr. Rheum., 1996, 39, 20212027</p><p>Clegg L.J., Reda D.J., Abdellatif M. Comparison of sulfasalazine for the treatment and placebo of axial and peripherial articular manifestations of the seronegative spondyloarthropathies. Arthr. Rheum., 1999. 42, 2325-2329</p><p>Combe B., Goupille P., Kuntz J.L. et al. Sulphasalazine in psoriatic arthritis: a randomized, multicentre, placebo-controlled study. Br. J. Rheumatol., 1996, 35, 664-668</p><p>Dougados М., Chaussade S. Treatment of inflammatory bowel disease-related arthropathies. Rheumatol, in Europe, 1997, 26,1, 27-30</p><p>Dougados М., Dormans B., Khan M. et al, Conventional treatments for ankylosing spondylitis. Ann. Rheum. Dis., 2002, 61. suppl. Ill, 40-50</p><p>Dougados М., Revel М., Khan M. Spondyloarthropathy treatment: progress in medical treatment, physical therapy and rehabilitation. Baillares Clin. Rheumatol., 1998, 12, 717-736</p><p>Dougados M.t van der Linden S., Leirisalo-Repo M. el al. Sulphasalazine in the treatment of spondylarthropathy. Arthr. Rheum., 1995, 38, 618-627</p><p>Egsmose C. Hansen Т., Andersen L.S. et al. Limited effect of sulphasalazine treatment in reactive arthritis. A ran нарастающей функциональной недостаточности опорнодвигательного аппарата. При периферической и ризомели- ческой формах идиопатического АС, ПА, протекающего с умеренной активностью воспаления, и особенно при арт- ропатиях, ассоциированных с хроническими воспалительными заболеваниями кишечника, сульфасалазин является препаратом, которому следует отдавать предпочтение перед другими болезнь-модифицируюшими средствами. domised double blind placebo controlled trial. Ann. Rheum. Dis., 1997, 56, 32-36</p><p>Ferraz M.B., Tugwell P., Goldsmith C.H., Atra E. Metaanalysis of sulphasalazine in ankylosing spondyliiis. J. Rheumatol., 1990, 17,1482-1486</p><p>Fraser S.М., Hopkins R., Hunter J.A. et al. Sulphasalazine in the management of psoriatic arthritis. Br. J. Rheumatol., 1993, 32, 923-925</p><p>Fuchs H.A. Use of sulphasalazine in rheumatic diseases. Bull. Rheum. Dis., 1997, 46. 3</p><p>Gladman D.D. Effictiveness of psoriatic arthritis. Sem, Arthr. Rheum., 2003, 33,1, 29-37</p><p>Goedcoop A.Y., Kraan M.C., Teunissen M.B.M. et al. Early effects of tumor necrosis factor a blocade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann. Rheum. Dis., 2004, 63, 769-773</p><p>Gran J. Т., Husby G. Clinical, epidemiologic, and therapeutic aspects of ankylosing sponddylilis. Curr. Opin. Rheumatol., 1998, 10. 292-298</p><p>Gupta A.K., Grober J.S., Hamilton T.A. el ai. Sulphasalazine therapy for psoriatic arthritis: a double blend placebo controlled trial. J. Rheumatol., 1995, 22. 894-898</p><p>Hanauser S.B., Stathopoulos G. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease. Drug Saf, 1991, 6, 192-219</p><p>Jones G., Crotty М., Brooks P. Interventions for treating psoriatic arthritis. Cochrane Database Syst. Rev., 2000, 3, CD0002I2.</p><p>Kahn V.V. Ankylosing spondylitis - the history of medical therapies. Clin. Exp. Rheumatol., 2002, 20, suppl.28, 3-5.</p><p>Kohler L., Kuipers J.G., Zeidler H. Managing seronegative spondarthritides. Rheumatol., 2000, 39, 360-368</p><p>McGonagle D., Khan M.A., Mazzo-Ortega H. -et al. Enlhesitis in spondyloarthritis. Curr. Opin. Rheumatol., 1999, II, 4, 244-250</p><p>Mease P. TNFa therapy in psoriatic arthritis and psoriasis, Ann. Rheum. Dis., 2004, 63, 755-758</p><p>Peppercorn M.A. Sulphasalazine: pharmacology, clinical use, toxicity and related new drug development. Ann, Intern. Med., 1984, 101, 377-386</p><p>Rahman P., Gladman D.D., Thorne J.C. et al. The use of sulphasalazine in psoriatic arthritis: a clinical experience. J. Rheumatol., 1998, 25, 1957-1961</p><p>Sieper J., Braun J., Rudwaleit M. et al. Ankylosing: an overview. Ann. Rheum. Dis. 2002. 61, suppl. III. 8-18.</p><p>Salvarani C., Macchioni P., Olivieri I. et al. A comparison of cyclosporine, sulphasalazine, and symptomatic therapy in the treatment of psoriatic arhritis. J. Rheumatol., 2001,28. 10, 2274-2282</p><p>Taggard A.J., Gardiner P.V., McEwoy F.M. et al. Which is the active moiety of sulphasalazine in ankylosing spondylitis? Arthr. Rheum., 1996, 39, 1400-1405</p><p>Veale D.J., FitzGerald O. Psoriatic arthritis - pathogenesis and epidemiology. Clin. Exp. Rheumatol., 2002. 20, 6, suppl. 28, 27-33</p><p>Ward M.M., Kuzis S. Treatment used by patients with ankylosing spondylitis: comparison with treatment preferences of rheumatologists. J. Clin. Rheunatol., 1999, 5, 1-8</p><p>Wolf R., Ruocco V. Triggered psoriasis. KheumayDerin 97,Malta, 1997</p></div><br /><div><p>Бадокин В.В., Агабабова Э.Р., Шубин С.В. Место глюкокортикостероидов в терапии серонегативных спон- дилоартритов. Научно-практическая ревматология, 2001, 4, 48-55</p><p>Насонова В.А., Насонов ЕЛ. Рациональная фармакотерапия ревматических заболеваний. М., Литтерра, 2003</p><p>Чепелева С.Н., Сигиднн Я.А., Лукина Г.В. Контролируемая оценка эффективности сульфасалазина при ан- килозирующем спондилоартрите. Научно-пракгич. ревматол., 2001, 4, 32-36</p><p>Altan L., Bingo! U., Karakos Y. et al. Clinical investigation of methotrexate in the treatment of ankylosing spondylitis. Scand. J. Rheumatol. 2001, 30, 255-259</p><p>Amor B. Data management in spondylarthropathies. Rheumatol, in Europe, 1996, 25, 92-95</p><p>Amor B., Dougados М., Kahn M.A. Management of refractory ankylosing spondylitis and related spondyloarthropathies. Rheum. Dis. North Am., 1995, 21, 117-126</p><p>Brandt J., Buss B., Sieper J., Braun.1. Efficacy of treatment with sulphasalazine versus azathioprine in ankylosing spondylitis. J. Rheumatol. 2000, 27, suppl. 59, 182-184</p><p>Braun J, Sieper J. Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases. Expert Opin. Biol. Ther., 2003, 3, 141-168</p><p>Calin A., Tnurog J.D. Spondylarthritides. Oxford University Press, 1998</p><p>Clegg D.O., Reda D.J., Mejias E. et al. Comparison of sulphasalazine and placebo for the treatment of psoriatic arthritis and cutaneous psoriasis. Arthr. Rheum., 1996, 39, 2013-2020</p><p>Clegg D.O., Rede D.J., Weisman M.N. et al. Comparison of sulphasalazine and placebo in the treatment of reactive arthritis (Reiterys syndrome). A Department of Veterans Affairs Cooperative study. Arthr. Rheum., 1996, 39, 20212027</p><p>Clegg L.J., Reda D.J., Abdellatif M. Comparison of sulfasalazine for the treatment and placebo of axial and peripherial articular manifestations of the seronegative spondyloarthropathies. Arthr. Rheum., 1999. 42, 2325-2329</p><p>Combe B., Goupille P., Kuntz J.L. et al. Sulphasalazine in psoriatic arthritis: a randomized, multicentre, placebo-controlled study. Br. J. Rheumatol., 1996, 35, 664-668</p><p>Dougados М., Chaussade S. Treatment of inflammatory bowel disease-related arthropathies. Rheumatol, in Europe, 1997, 26,1, 27-30</p><p>Dougados М., Dormans B., Khan M. et al, Conventional treatments for ankylosing spondylitis. Ann. Rheum. Dis., 2002, 61. suppl. Ill, 40-50</p><p>Dougados М., Revel М., Khan M. Spondyloarthropathy treatment: progress in medical treatment, physical therapy and rehabilitation. Baillares Clin. Rheumatol., 1998, 12, 717-736</p><p>Dougados M.t van der Linden S., Leirisalo-Repo M. el al. Sulphasalazine in the treatment of spondylarthropathy. Arthr. Rheum., 1995, 38, 618-627</p><p>Egsmose C. Hansen Т., Andersen L.S. et al. Limited effect of sulphasalazine treatment in reactive arthritis. A ran нарастающей функциональной недостаточности опорнодвигательного аппарата. При периферической и ризомели- ческой формах идиопатического АС, ПА, протекающего с умеренной активностью воспаления, и особенно при арт- ропатиях, ассоциированных с хроническими воспалительными заболеваниями кишечника, сульфасалазин является препаратом, которому следует отдавать предпочтение перед другими болезнь-модифицируюшими средствами. domised double blind placebo controlled trial. Ann. Rheum. Dis., 1997, 56, 32-36</p><p>Ferraz M.B., Tugwell P., Goldsmith C.H., Atra E. Metaanalysis of sulphasalazine in ankylosing spondyliiis. J. Rheumatol., 1990, 17,1482-1486</p><p>Fraser S.М., Hopkins R., Hunter J.A. et al. Sulphasalazine in the management of psoriatic arthritis. Br. J. Rheumatol., 1993, 32, 923-925</p><p>Fuchs H.A. Use of sulphasalazine in rheumatic diseases. Bull. Rheum. Dis., 1997, 46. 3</p><p>Gladman D.D. Effictiveness of psoriatic arthritis. Sem, Arthr. Rheum., 2003, 33,1, 29-37</p><p>Goedcoop A.Y., Kraan M.C., Teunissen M.B.M. et al. Early effects of tumor necrosis factor a blocade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann. Rheum. Dis., 2004, 63, 769-773</p><p>Gran J. Т., Husby G. Clinical, epidemiologic, and therapeutic aspects of ankylosing sponddylilis. Curr. Opin. Rheumatol., 1998, 10. 292-298</p><p>Gupta A.K., Grober J.S., Hamilton T.A. el ai. Sulphasalazine therapy for psoriatic arthritis: a double blend placebo controlled trial. J. Rheumatol., 1995, 22. 894-898</p><p>Hanauser S.B., Stathopoulos G. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease. Drug Saf, 1991, 6, 192-219</p><p>Jones G., Crotty М., Brooks P. Interventions for treating psoriatic arthritis. Cochrane Database Syst. Rev., 2000, 3, CD0002I2.</p><p>Kahn V.V. Ankylosing spondylitis - the history of medical therapies. Clin. Exp. Rheumatol., 2002, 20, suppl.28, 3-5.</p><p>Kohler L., Kuipers J.G., Zeidler H. Managing seronegative spondarthritides. Rheumatol., 2000, 39, 360-368</p><p>McGonagle D., Khan M.A., Mazzo-Ortega H. -et al. Enlhesitis in spondyloarthritis. Curr. Opin. Rheumatol., 1999, II, 4, 244-250</p><p>Mease P. TNFa therapy in psoriatic arthritis and psoriasis, Ann. Rheum. Dis., 2004, 63, 755-758</p><p>Peppercorn M.A. Sulphasalazine: pharmacology, clinical use, toxicity and related new drug development. Ann, Intern. Med., 1984, 101, 377-386</p><p>Rahman P., Gladman D.D., Thorne J.C. et al. The use of sulphasalazine in psoriatic arthritis: a clinical experience. J. Rheumatol., 1998, 25, 1957-1961</p><p>Sieper J., Braun J., Rudwaleit M. et al. Ankylosing: an overview. Ann. Rheum. Dis. 2002. 61, suppl. III. 8-18.</p><p>Salvarani C., Macchioni P., Olivieri I. et al. A comparison of cyclosporine, sulphasalazine, and symptomatic therapy in the treatment of psoriatic arhritis. J. Rheumatol., 2001,28. 10, 2274-2282</p><p>Taggard A.J., Gardiner P.V., McEwoy F.M. et al. Which is the active moiety of sulphasalazine in ankylosing spondylitis? Arthr. Rheum., 1996, 39, 1400-1405</p><p>Veale D.J., FitzGerald O. Psoriatic arthritis - pathogenesis and epidemiology. Clin. Exp. Rheumatol., 2002. 20, 6, suppl. 28, 27-33</p><p>Ward M.M., Kuzis S. Treatment used by patients with ankylosing spondylitis: comparison with treatment preferences of rheumatologists. J. Clin. Rheunatol., 1999, 5, 1-8</p><p>Wolf R., Ruocco V. Triggered psoriasis. KheumayDerin 97,Malta, 1997</p></div><br />
The authors declare that there are no conflicts of interest present.